<i>HRness</i> in Breast and Ovarian Cancers

<i>HRness</i> in Breast and Ovarian Cancers

Ovarian and breast cancers are currently defined by the main pathways involved in the tumorigenesis. The majority are carcinomas, originating from epithelial cells that are in constant division and subjected to cyclical variations of the estrogen stimulus during the female hormonal cycle, therefore...

Full description

Bibliographic Details
Main Authors:	Elizabeth Santana dos Santos, François Lallemand, Ambre Petitalot, Sandrine M. Caputo, Etienne Rouleau
Format:	Article
Language:	English
Published:	MDPI AG 2020-05-01
Series:	International Journal of Molecular Sciences
Subjects:	homologous recombination deficiency DNA repair breast cancer tumorigenesis ovarian cancer tumorigenesis BRCA1 BRCA2
Online Access:	https://www.mdpi.com/1422-0067/21/11/3850

Similar Items

Targeting Homologous Recombination Deficiency in Ovarian Cancer with PARP Inhibitors: Synthetic Lethal Strategies That Impact Overall Survival
by: Tao Xie, et al.
Published: (2022-09-01)

Exploiting the Prevalence of Homologous Recombination Deficiencies in High-Grade Serous Ovarian Cancer
by: Sara Bouberhan, et al.
Published: (2020-05-01)

Homologous recombination deficiency in ovarian cancer: a review of its epidemiology and management
by: Renata Rodrigues da Cunha Colombo Bonadio, et al.
Published: (2018-08-01)

Maintenance Treatment of Newly Diagnosed Advanced Ovarian Cancer: Time for a Paradigm Shift?
by: Paul DiSilvestro, et al.
Published: (2021-11-01)

Integration of PARP-inhibitors in ovarian cancer therapy
by: Antonella Pietragalla, et al.
Published: (2020-06-01)

An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers
by: Ewa Przybytkowski, et al.
Published: (2020-03-01)

A Pan-Canadian Consensus Statement on First-Line PARP Inhibitor Maintenance for Advanced, High-Grade Serous and Endometrioid Tubal, Ovarian, and Primary Peritoneal Cancers
by: Anna V. Tinker, et al.
Published: (2022-06-01)

Development of a Genomic Signatures-Based Predictor of Initial Platinum-Resistance in Advanced High-Grade Serous Ovarian Cancer Patients
by: Yuan Li, et al.
Published: (2021-03-01)

Preclinical Studies on the Effect of Rucaparib in Ovarian Cancer: Impact of BRCA2 Status
by: Sayeh Saravi, et al.
Published: (2021-09-01)

Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer: design, development and place in therapy
by: Lorusso D, et al.
Published: (2018-05-01)

BRCA1, BRCA2, and TP53 germline and somatic variants and clinicopathological characteristics of Brazilian patients with epithelial ovarian cancer
by: Caroline Stahnke Richau, et al.
Published: (2024-02-01)

Non-Coding Variants in <i>BRCA1</i> and <i>BRCA2</i> Genes: Potential Impact on Breast and Ovarian Cancer Predisposition
by: Elizabeth Santana dos Santos, et al.
Published: (2018-11-01)

Germline Mutations in Other Homologous Recombination Repair-Related Genes Than <i>BRCA1/2</i>: Predictive or Prognostic Factors?
by: Laura Cortesi, et al.
Published: (2021-03-01)

PARP Inhibitors Display Differential Efficacy in Models of <i>BRCA</i> Mutant High-Grade Serous Ovarian Cancer
by: Kristie-Ann Dickson, et al.
Published: (2021-08-01)

Efficacy and Prognostic Factors for PARP Inhibitors in Patients With Ovarian Cancer
by: Xuan-zhang Huang, et al.
Published: (2020-06-01)

Dynamically Accumulating Homologous Recombination Deficiency Score Served as an Important Prognosis Factor in High-Grade Serous Ovarian Cancer
by: Rongjia Su, et al.
Published: (2021-11-01)

The RECAP Test Rapidly and Reliably Identifies Homologous Recombination-Deficient Ovarian Carcinomas
by: Lise M. van Wijk, et al.
Published: (2020-09-01)

Functional Homologous Recombination (HR) Screening Shows the Majority of <i>BRCA1/2</i>-Mutant Breast and Ovarian Cancer Cell Lines Are HR-Proficient
by: Titia G. Meijer, et al.
Published: (2024-02-01)

The Elephant and the Blind Men: Making Sense of PARP Inhibitors in Homologous Recombination Deficient Tumor Cells
by: Silvana eDe Lorenzo, et al.
Published: (2013-09-01)

Clinical application of PARP inhibitors in ovarian cancer: from molecular mechanisms to the current status
by: Yongsong Wu, et al.
Published: (2023-01-01)

Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer
by: Colombo I, et al.
Published: (2018-03-01)

How BRCA and homologous recombination deficiency change therapeutic strategies in ovarian cancer: a review of literature
by: Martina Arcieri, et al.
Published: (2024-03-01)

Targeted Combination of Poly(ADP-ribose) Polymerase Inhibitors and Immune Checkpoint Inhibitors Lacking Evidence of Benefit: Focus in Ovarian Cancer
by: Morgan Bailey, et al.
Published: (2024-03-01)

Clinical Implications of DNA Repair Defects in High-Grade Serous Ovarian Carcinomas
by: Michela Camilla Milanesio, et al.
Published: (2020-05-01)

The evolving role of PARP inhibitors in advanced ovarian cancer
by: Levva Sofia, et al.
Published: (2021-08-01)

Mitomycin C in Homologous Recombination Deficient Metastatic Pancreatic Cancer after Disease Progression on Platinum-Based Chemotherapy and Olaparib
by: Gehan Botrus, et al.
Published: (2022-10-01)

Olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer
by: S V Khokhlova
Published: (2017-09-01)

The use of PARP inhibitor - olaparib for the treatment of ovarian cancer in clinical practice
by: S V Khokhlova
Published: (2016-12-01)

PARP Inhibitors for Breast Cancer: Germline <em>BRCA1/2</em> and Beyond
by: Maria Clara Saad Menezes, et al.
Published: (2022-09-01)

The Ethnic-Specific Spectrum of Germline Nucleotide Variants in DNA Damage Response and Repair Genes in Hereditary Breast and Ovarian Cancer Patients of Tatar Descent
by: Olga I. Brovkina, et al.
Published: (2018-10-01)

Next-generation sequencing-based analysis of homologous recombination repair gene variant in ovarian cancer
by: Yaolin Song, et al.
Published: (2024-01-01)

Management of BRCA Tumour Testing in an Integrated Molecular Tumour Board Multidisciplinary Model
by: Jacopo Azzollini, et al.
Published: (2022-04-01)

Tailoring Ovarian Cancer Treatment: Implications of <i>BRCA1/2</i> Mutations
by: Ainhoa Madariaga, et al.
Published: (2019-03-01)

Reviewing the characteristics of BRCA and PALB2-related cancers in the precision medicine era
by: Gabriel S. Macedo, et al.
Published: (2019-04-01)

PARP Inhibitors in Patients With Newly Diagnosed Advanced Ovarian Cancer: A Meta-Analysis of Randomized Clinical Trials
by: Yizi Wang, et al.
Published: (2020-08-01)

PARP Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination Therapies
by: Elizabeth K. Lee, et al.
Published: (2020-07-01)

BRCA1 and BRCA2 and Inherited Predisposition to Breast and Ovarian Cancers
by: Patricia N. Tonin
Published: (2002-12-01)

Tumor Genotyping and Homologous Recombination Repair Gene Variants in Patients With Epithelial Ovarian Cancer: Is Pathogenic Enough?
by: Elena Fountzilas, et al.
Published: (2021-06-01)

Homologous recombination deficiency in diverse cancer types and its correlation with platinum chemotherapy efficiency in ovarian cancer
by: Hao Wen, et al.
Published: (2022-05-01)

CHEK2 1100 delC mutation in Russian ovarian cancer patients
by: Krylova Nadezhda, et al.
Published: (2007-09-01)